Treatment of chronic hepatitis B: focus on telbivudine

References

• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology34(6), 1225–1241 (2001).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Kao JH et al. Asian–Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int.2, 263–283 (2008).
   PubMed Web of Science ®Google Scholar
• Chan HLY, Sung JJY. Hepatocellular carcinoma and hepatitis B virus. Semin. Liver Dis.26(2), 153–161 (2006).
   PubMed Web of Science ®Google Scholar
• Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol. Clin. North Am.23(3), 437–455 (1994).
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA295(1), 65–73 (2006).
   PubMed Web of Science ®Google Scholar
• Chen G, Lin W, Shen F et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol.101(8), 1797–1803 (2006).
   PubMed Web of Science ®Google Scholar
• Chan HLY, Tse CH, Mo F et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J. Clin. Oncol.26(2), 177–182 (2008).
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J et al. HBV viral load less than 104 copies/ml is associated with significant risk of hepatocellular carcinoma in chronic hepatitis B patients: an update from the R.E.V.E.A.L.-HBV study. Hepatology46(Suppl. 1), 640A (2007).
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology130(3), 678–686 (2006).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med.351(15), 1521–1531 (2004).
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology45(2), 507–539 (2007).
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol.50(2), 227–242 (2009).
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendation. Hepatology39(3), 857–861 (2004).
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX et al. Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med.352(26), 2682–2695 (2005).
   PubMed Web of Science ®Google Scholar
• Chan HL, Leung NW, Hui AY et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-α2b and lamivudine with lamivudine alone. Ann. Intern. Med.142(4), 240–250 (2005).
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet365(9454), 123–129 (2005).
   PubMed Web of Science ®Google Scholar
• Chan HL, Hui AY, Wong VW et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology41(6), 1357–1364 (2005).
   PubMed Web of Science ®Google Scholar
• Buster EH, Flink HJ, Cakaloglu Y et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b. Gastroenterology135(2), 459–467 (2008).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Piratvisuth T, Brunetto M et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatotos B treated with peginterferon α-2a (4oKD) with or without lamivudine: results of 4-year follow-up. J. Hepatol.48(Suppl. 2), S46 (2008).
   Google Scholar
• Marcellin P, Lau GK, Bonino F et al. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med.351(12), 1206–1217 (2004).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology131(6), 1734–1751 (2006).
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chornic hepatitis B. N. Engl. J. Med.354(10), 1001–1010 (2006).
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med.354(10), 1011–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Bryant ML, Bridges EG, Placidi L et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother.45(1), 229–235 (2001).
   PubMed Web of Science ®Google Scholar
• Standring DN, Bridges EG, Placidi L et al. Antiviral β-L-nucleosides specific for hepatitis B virus infection. Antivir. Chem. Chemother.12(Suppl. 1), 119–129 (2001).
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Lim SG, Lloyd DM et al. Pharmacokinetics of telbivudine following administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacokinetic implications. Antimicrob. Agents Chemother.50(3), 874–879 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Lloyd DM, Chao GC et al. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J. Clin. Pharmacol.46(3), 275–281 (2006).
   PubMed Web of Science ®Google Scholar
• Hu P, Jiang J, Wang H et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J. Clin. Pharmacol.46(9), 999–1007 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Marbury TC, Alcorn HW et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob. Agents Chemother.50(5), 1721–1726 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Swan S, Smith WB et al. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Antimicrob. Agents Chemother.51(12), 4231–4235 (2007).
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Fielman BA, Lloyd DM et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob. Agents Chemother.50(7), 2309–2315 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Pietropaolo K, Becker M et al. Absence of pharmacokinetic drug–drug interaction between telbivudine and tenofovir. Gastroenterology132(Suppl. 2), A766 (2007).
   Google Scholar
• Zhou XJ, Fielman B, Dubuc-Patrick G et al. Absence of pharmacokinetic drug–drug interaction between telbivudine and peginterferon α-2a or cyclosporine in healthy subjects. J. Hepatol.44(Suppl. 2), S194 (2006).
   Web of Science ®Google Scholar
• Bridges EG. Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity. J. Hepatol.44(Suppl. 2), S147 (2006).
   Web of Science ®Google Scholar
• Lai CL, Lim SG, Brown NA et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology40(3), 719–726 (2004).
   PubMed Web of Science ®Google Scholar
• Lai CL, Leung N, Teo EK et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology129(2), 528–536 (2005).
   PubMed Web of Science ®Google Scholar
• Lai CL, Leung N, Teo EK et al. Phase IIb extended-treatment trial of telbivudine (LDT) vs lamivudine vs combination treatment in hepatitis B patients: two-year results. Gastroenterology128(Suppl. 2), A692 (2005).
   Google Scholar
• Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chornic hepatitis B. N. Engl. J. Med.357(25), 2576–2588 (2007).
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Hsu CW et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs lamivudine. Hepatology44(Suppl. 1), A222 (2006).
   Google Scholar
• Di Bisceglie AM, Lai CL, Gane E et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology44(Suppl. 1), 230A (2006).
   Google Scholar
• Gane EJ, Wong Y, Buti M et al. Continued telbivudine treatment results in high rates of maintained response in HBeAg-postivie patients at 3 years. Hepatology48(Suppl. 1), 729A (2008).
   Web of Science ®Google Scholar
• Hou J, Yin YK, Xu D et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology47(2), 447–454 (2008).
   PubMed Web of Science ®Google Scholar
• Safadi R, Xie Q, Chen Y et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24. J. Hepatol.46(Suppl. l), S196–S197 (2007).
   Web of Science ®Google Scholar
• Chan HLY, Heathcote EJ, Marcellin P et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann. Intern. Med.147(11), 745–754 (2007).
   PubMed Web of Science ®Google Scholar
• Chan HLY, Wang H, Niu J et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir. Ther.12(3), 345–353 (2007).
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Chien RN et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol.19(11), 1276–1282 (2004).
   PubMed Web of Science ®Google Scholar
• Ding C, Wong VWS, Chow K et al. Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy. Antivir. Ther.11(8), 1041–1049 (2006).
   PubMed Web of Science ®Google Scholar
• Brown CA, Smithz F, Laessig KA et al. Creatine kinase (CK) elevations and muscle toxicities associated with chronic telbivudine (LDT) use in prospective clinical trials. Hepatology46(Suppl. 1), 655A (2007).
   Google Scholar
• Zhang XS, Jin R, Zhang SB et al. Clinical features of adverse reactions associated with telbivudine. World J. Gastroenterol.14(22), 3549–3553 (2008).
   PubMed Web of Science ®Google Scholar
• Heathcote E, Gane EJ, deMan RA et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatology48(Suppl. 1), 376A (2008).
   Google Scholar
• Marcellin P, Buti M, Krastev Z et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis. Hepatology48(Suppl. 1), 370A (2008).
   Web of Science ®Google Scholar
• Suh DJ, Herrmann E, Zeuzem S et al. Head-to-head comparison of viral kinetics of telbivudine and entecavir in patients with chronic hepatitis B over the first 12 weeks of treatment. Hepatology48(Suppl. 1), 191A (2008).
   Google Scholar
• Tenney DJ, Pokornowski KA, Rose RE et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol. Int.2, A88 (2008).
   Google Scholar
• Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol. Int.2(3), 284–295 (2008).
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Zeuzem S, Koff RS et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol.5(8), 890–897 (2007).
   PubMed Web of Science ®Google Scholar
• van Nunen AB, Hansen BE, Suh DJ et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut52(3), 420–424 (2003).
   PubMed Web of Science ®Google Scholar
• Chan HLY, Wong ML, Hui AY et al. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J. Gastroenterol.9(12), 2695–2697 (2003).
   PubMed Web of Science ®Google Scholar
• Chan HLY, Wong VWS, Tse AML et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin. Gastroenterol. Hepatol.5(12), 1462–1468 (2007).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med.348(9), 808–816 (2003).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopouios NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med.348(9), 800–807 (2003).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dioivoxiol for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients. Hepatology44(Suppl. 1), 548A (2006).
   Google Scholar
• Heathcote J, George J, Gordon S et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103). J. Hepatol.48(Suppl. 2), S32 (2008).
   Web of Science ®Google Scholar
• Marcellin P, Jacobson I, Habersetzer F et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102). J. Hepatol.48(Suppl. 2), S26 (2008).
   Web of Science ®Google Scholar
• Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology133(5), 1437–1444 (2007).
   PubMed Web of Science ®Google Scholar
• Shouval D, Akarca U, Hatzis G et al. Continues virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg-chronic hepatitis B patients (study ETV-027). J. Hepatol.130(Suppl. 1), S21–S22 (2006).
   Google Scholar